News: Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

14.21USD
19 Dec 2014
Price Change (% chg)

$-0.34 (-2.30%)
Prev Close
$14.55
Open
$14.36
Day's High
$14.54
Day's Low
$13.90
Volume
6,566,041
Avg. Vol
5,669,208
52-wk High
$16.87
52-wk Low
$2.45

Search Stocks
Select another date:

Achillion data shows promise of shorter-duration hep C treatment

- Data from Achillion Pharmaceuticals Inc's hepatitis C drug trials showed the company could develop a shorter-duration treatment rivaling offerings from Gilead Sciences Inc and Abbvie Inc.

UPDATE 1-Achillion data shows promise of shorter-duration hep C treatment

* Achillion's NS5A inhibitor superior to Gilead's - analysts

Achillion shares soar as potential treatment seen as hep C cure

Dec 22 - Achillion Pharmaceuticals Inc said it would test a combination of two of its experimental hepatitis C drugs after they showed promise against the virus in separate studies.

Achillion's hepatitis C drug shows promise in trial

- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent.

UPDATE 1-Achillion's hepatitis C drug shows promise in trial

(Adds details, analysts' comments on data, share movement)

Achillion's hepatitis C drug cures all patients in mid-stage trial

Aug 15 - Achillion Pharmaceuticals Inc said interim results from a mid-stage trial showed that all patients given its experimental hepatitis C drug showed no detectable levels of the virus four weeks after completing the therapy.

Select another date:
Search Stocks